Horizon Therapeutics initiates PROTECT clinical trial of KRYSTEXXA

Image: KRYSTEXXA is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Photo: Courtesy of PublicDomainPictures from Pixabay.